FDA rejects China-developed cancer drug Ivonescimab, setback for Beijing biotech
Published 15 h ago2 sourcesEvidence: Reported
The FDA has rejected ivonescimab, a bispecific antibody for non-small cell lung cancer developed by Summit Therapeutics and China's Akeso. The rejection is a major setback for Summit, which had bet heavily on the drug's approval. The decision raises uncertainty about the drug's regulatory path and its competitive position against existing PD-1 inhibitors.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Entities
Published 15 h ago2 sourcesEvidence: Reported
Published 3 h ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 h ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 10 h ago1 sourceEvidence: Reported